Blood Cancers

Overview

Curcumin has encouraging but still early evidence in several blood cancers.

The strongest human signals are in multiple myeloma, MGUS or smouldering myeloma, and early-stage CLL. Most other blood-cancer evidence remains preclinical.

Curcumin is best understood here as an adjunct under investigation. It is not an established treatment for haematologic malignancy.

How curcumin may work in blood cancers

Across blood-cancer models, curcumin appears to act through several recurring pathways:

• suppressing NF-κB, JAK/STAT, MAPK, and Wnt/β-catenin signalling

• inducing apoptosis through caspase-3, AIF, and PARP-1 cleavage

• reducing pro-survival signalling such as Bcl-2

• affecting stemness and resistance markers including Gli-1, Notch-1, Cyclin D1, and HOTAIR

• lowering inflammatory and angiogenic signals such as TNF-α, IL-6, and VEGF

This matters because these pathways sit close to proliferation, survival, treatment resistance, and microenvironment signalling in many haematologic cancers.

Multiple myeloma and MGUS / smouldering myeloma

This is the most developed blood-cancer niche for curcumin.

In a small randomised clinical trial, adding curcumin to melphalan-prednisone for 28 days was associated with higher remission rates and larger reductions in NF-κB, VEGF, TNF-α, and IL-6 than control treatment alone.

Long-term follow-up work in MGUS and smouldering myeloma has also reported improvement in free light chain ratio and paraprotein trends in subsets of patients.

A published case report described prolonged disease stabilisation in a treatment-resistant myeloma setting after standard options had been exhausted. That signal is interesting, but it remains hypothesis-generating only.

Leukaemias

Leukaemia evidence is mixed across subtypes.

In pre-B acute lymphoblastic leukaemia cell lines, curcumin caused dose-dependent loss of viability and increased apoptosis markers including caspase-3, AIF, and cleaved PARP-1, while lowering Bcl-2.

At lower experimental doses, curcumin also enhanced doxorubicin-induced cell death in these ALL models. That supports chemosensitisation interest, but only at preclinical level.

In early-stage CLL and SLL, a phase II study combining curcumin with high-dose vitamin D reported that the regimen was safe and well tolerated. That did not establish curcumin as a disease-modifying standard, but it supports ongoing interest in watch-and-wait or low-burden settings.

Reviews also describe effects on stem-cell and resistance biology in leukaemia models, including Gli-1, Notch-1, Cyclin D1, and HOTAIR.

Lymphomas and other haematologic malignancies

Human lymphoma-specific data remain very limited.

The main signal comes from preclinical work. In lymphoma-bearing mice, curcumin suppressed NF-κB signalling and inhibited tumour growth in vivo.

Broader haematology reviews place lymphoma within a wider pattern of pathway-level activity across blood cancers, but this is still far from proof of clinical benefit.

Clinical positioning

The current picture is uneven:

• strongest clinical interest: multiple myeloma, MGUS, smouldering myeloma, and early-stage CLL

• strongest preclinical interest: ALL, broader leukaemia models, lymphoma, and resistance biology

• main limitation: human studies are small, early, and not sufficient to prove survival benefit

Current oncology summaries still position curcumin as a complementary agent under investigation, not an established therapy.

Formulation and dosing context

Most blood-cancer studies used standard oral curcumin rather than newer liposomal, micellar, or nanoparticle products.

Typical human study doses were often high by supplement standards, commonly around 4 to 8 g/day of oral curcumin.

Some protocols added piperine to raise systemic exposure. That improves bioavailability, but it also raises interaction concerns.

This means the blood-cancer literature contains more clinical experience with older, less bioavailable curcumin formats than with newer delivery systems.

Practical safety considerations

Curcumin has generally been well tolerated in the early blood-cancer studies, with gastrointestinal upset as the most common adverse effect.

The main practical cautions are:

• possible CYP and P-glycoprotein interactions with chemotherapy or targeted therapy

• stronger interaction potential when piperine is added

• mild antiplatelet activity, which may matter in thrombocytopenia or when anticoagulants are being used

In blood-cancer settings, that makes treatment-review input especially important before adding high-dose curcumin.

Practical interpretation

Curcumin is biologically active in blood-cancer research.

The most credible current use case is as a possible adjunct in carefully selected settings, especially myeloma-spectrum disease and early-stage CLL, with full attention to formulation and drug-interaction risk.

Human evidence remains too limited to treat curcumin as a standard blood-cancer therapy. Standard haematology care should remain the priority.

Key References

Curcumin in treatment of hematological cancers: Promises and challenges
https://pmc.ncbi.nlm.nih.gov/articles/PMC10927384/

Curcumin Induces Apoptosis in Pre-B Acute Lymphoblastic Leukemia Cell Lines Via PARP-1 Cleavage
https://pubmed.ncbi.nlm.nih.gov/27644631/

Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial
https://pmc.ncbi.nlm.nih.gov/articles/PMC9301229/

Long-term follow-up of curcumin treated MGUS/SMM patients – an updated single centre experience
https://www.oatext.com/long-term-follow-up-of-curcumin-treated-mgus-smm-patients-an-updated-single-centre-experience.php

Long-term stabilisation of myeloma with curcumin
https://casereports.bmj.com/content/2017/bcr-2017-220544

Study Details | NCT00113841 | Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma
https://clinicaltrials.gov/study/NCT00113841

Study Details | NCT04731844 | Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
https://clinicaltrials.gov/study/NCT04731844

Curcumin and Cancer (PDQ®)
https://www.cancer.gov/about-cancer/treatment/cam/patient/curcumin-pdq